See more : ADM Energy plc (ADME.L) Income Statement Analysis – Financial Results
Complete financial analysis of Medicine Man Technologies, Inc. (SHWZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicine Man Technologies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- National Silicon Industry Group Co., Ltd. (688126.SS) Income Statement Analysis – Financial Results
- UBS Group AG (0R3T.L) Income Statement Analysis – Financial Results
- Wenzhou Yuanfei pet toy products Co., Ltd. (001222.SZ) Income Statement Analysis – Financial Results
- Shree Ganesh Elastoplast Limited (SHGANEL.BO) Income Statement Analysis – Financial Results
- Good Fellow Healthcare Holdings Limited (8143.HK) Income Statement Analysis – Financial Results
Medicine Man Technologies, Inc. (SHWZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.schwazze.com
About Medicine Man Technologies, Inc.
Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. It operates through three segments: Retail, Wholesale, and Other. The company offers cannabis products that include loose flower, concentrates, edibles, pre-rolls, topicals, and other associated cannabis products; and vape cartridges and syringes. As of March 14, 2022, it owned and operated 23 retail cannabis dispensaries under the Star Buds, Smoking Gun Apothecary, Emerald Fields, and Drift banner names in Denver and Colorado; and 10 medical retail cannabis dispensaries under the R. Greenleaf banner in New Mexico. The company also provides licensing and consulting, facility design, and facility management services; and Three A Light publication. In addition, it manufactures, wholesales, and retails various plant nutrients for cannabis; and supplies hydroponics and indoor gardening supplies. The company was incorporated in 2014 and is headquartered in Denver, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 172.45M | 159.38M | 108.42M | 24.00M | 10.62M | 7.92M | 3.53M | 631.46K | 835.78K | 251.89K |
| Cost of Revenue | 96.42M | 74.35M | 59.07M | 17.23M | 7.62M | 2.58M | 1.30M | 462.18K | 209.75K | 72.00K |
| Gross Profit | 76.02M | 85.03M | 49.35M | 6.77M | 3.00M | 5.35M | 2.23M | 169.27K | 626.03K | 179.89K |
| Gross Profit Ratio | 44.09% | 53.35% | 45.52% | 28.23% | 28.27% | 67.47% | 63.10% | 26.81% | 74.90% | 71.42% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 70.93M | 64.16M | 38.94M | 29.68M | 16.47M | 4.40M | 7.13M | 1.01M | 519.88K | 193.15K |
| Selling & Marketing | 0.00 | -34.77M | 0.00 | 0.00 | 0.00 | 291.71K | 183.78K | 311.52K | 16.00K | 15.50K |
| SG&A | 70.93M | 64.16M | 38.94M | 29.68M | 16.47M | 4.69M | 7.31M | 1.32M | 535.88K | 208.64K |
| Other Expenses | 1.80M | 24.14K | 22.33M | 32.62K | 11.99M | 1.37M | -70.04K | 165.02K | 0.00 | 0.00 |
| Operating Expenses | 72.73M | 64.16M | 38.94M | 29.68M | 16.47M | 4.69M | 7.31M | 1.32M | 535.88K | 208.64K |
| Cost & Expenses | 169.16M | 138.51M | 98.01M | 46.90M | 24.08M | 7.27M | 8.62M | 1.78M | 745.62K | 280.64K |
| Interest Income | 0.00 | 30.14M | 7.01M | 41.46K | 31.91K | 30.00K | 30.00K | 14.02K | 8.07K | 3.12K |
| Interest Expense | 32.07M | 30.14M | 7.01M | 41.46K | 192.11K | 0.00 | 86.02K | 125.16K | 0.00 | 1.18K |
| Depreciation & Amortization | 20.93M | 11.55M | 8.58M | 476.59K | 61.71K | 81.96K | 63.74K | 17.37K | 6.62K | 561.00 |
| EBITDA | 37.52M | 38.12M | 3.47M | -19.80M | -13.55M | 1.61M | -5.23M | -1.42M | 96.77K | -30.40K |
| EBITDA Ratio | 21.76% | 20.02% | 3.20% | -104.26% | -89.16% | 9.64% | -143.42% | -177.48% | 11.58% | -9.95% |
| Operating Income | 3.29M | 20.89M | -5.11M | -22.90M | -13.46M | 2.17M | -5.24M | -1.15M | 90.15K | -28.75K |
| Operating Income Ratio | 1.91% | 13.11% | -4.71% | -95.43% | -126.80% | 27.39% | -148.34% | -182.45% | 10.79% | -11.41% |
| Total Other Income/Expenses | -18.10M | -16.42M | 8.51M | 2.59M | -476.76K | -638.50K | -145.22K | -312.18K | 8.07K | 1.94K |
| Income Before Tax | -14.81M | -3.57M | 18.92M | -20.32M | -17.56M | 1.53M | -5.38M | -1.46M | 98.22K | -26.81K |
| Income Before Tax Ratio | -8.59% | -2.24% | 17.45% | -84.65% | -165.36% | 19.33% | -152.46% | -231.89% | 11.75% | -10.64% |
| Income Tax Expense | 19.74M | 14.90M | 4.40M | -899.11K | -582.93K | 582.93K | 15.98K | 125.16K | 12.48K | 3.14K |
| Net Income | -34.55M | -18.47M | 14.52M | -19.42M | -16.98M | 948.92K | -5.38M | -1.46M | 85.75K | -29.95K |
| Net Income Ratio | -20.03% | -11.59% | 13.39% | -80.90% | -159.87% | 11.97% | -152.46% | -231.89% | 10.26% | -11.89% |
| EPS | -0.26 | -0.34 | 0.17 | -0.47 | -0.50 | 0.03 | -0.23 | -0.14 | 0.01 | 0.00 |
| EPS Diluted | -0.26 | -0.34 | -0.06 | -0.47 | -0.50 | 0.03 | -0.23 | -0.14 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 64.54M | 53.64M | 43.34M | 41.22M | 33.74M | 27.77M | 22.99M | 10.23M | 9.91M | 9.84M |
| Weighted Avg Shares Out (Dil) | 64.54M | 53.64M | 101.37M | 41.22M | 33.74M | 27.77M | 22.99M | 10.23M | 9.91M | 9.97M |
Medicine Man Technologies, Inc. (SHWZ) CEO Justin Dye on Q4 2021 Results - Earnings Call Transcript
SCHWAZZE TO HOST YEAR-END 2021 CONFERENCE CALL & WEBCAST MARCH 31, 2022
Cannabis Stocks To Watch: Schwazze, Undervalued Consolidator
Schwazze: Undervalued Consolidator
Schwazze Enters New Mexico With Acquisition; Financing Positions For Further Expansion
Making The Case For Mid-Tier MSOs (Podcast)
Medicine Man Technologies, Inc. (SHWZ) CEO Justin Dye on Q3 2021 Results - Earnings Call Transcript
Schwazze to Host Third Quarter 2021 Conference Call & Webcast Nov 15, 2021
Schwazze Announces Participation at Benzinga, New York and MJBizCon, Las Vegas - October 2021
Schwazze Signs Definitive Agreement to Acquire Colorado Cultivation Grower Brow 2, LLC
Source: https://incomestatements.info
Category: Stock Reports